Niagen Bioscience (NASDAQ:NAGE) Stock Rating Lowered by Wall Street Zen

Niagen Bioscience (NASDAQ:NAGE) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Canaccord Genuity Group reduced their target price on Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Price Performance

NAGE opened at $5.06 on Friday. Niagen Bioscience has a one year low of $4.72 and a one year high of $14.69. The business has a 50 day simple moving average of $5.74 and a two-hundred day simple moving average of $7.14. The firm has a market capitalization of $405.20 million, a price-to-earnings ratio of 25.30 and a beta of 2.11.

Institutional Trading of Niagen Bioscience

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its position in shares of Niagen Bioscience by 5.7% during the fourth quarter. SG Americas Securities LLC now owns 54,649 shares of the company’s stock valued at $348,000 after buying an additional 2,950 shares during the last quarter. Swiss National Bank increased its holdings in Niagen Bioscience by 3.0% in the 4th quarter. Swiss National Bank now owns 110,100 shares of the company’s stock worth $700,000 after buying an additional 3,200 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Niagen Bioscience by 5.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,342 shares of the company’s stock worth $384,000 after buying an additional 3,215 shares during the last quarter. Financial Consulate Inc. purchased a new position in Niagen Bioscience in the 3rd quarter worth about $33,000. Finally, Wells Fargo & Company MN lifted its stake in Niagen Bioscience by 6.9% during the 4th quarter. Wells Fargo & Company MN now owns 58,337 shares of the company’s stock valued at $371,000 after acquiring an additional 3,740 shares during the period. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 beat and profit strength — Niagen reported quarterly EPS that topped estimates and stronger-than-expected revenue; media coverage notes the company doubled annual profit and management signaled an acquisition hunt and expansion into GLP‑1-style products, which drove significant after-hours buying interest. Niagen Bioscience Doubles Annual Profit (MSN)
• Positive Sentiment: Quarterly beat confirmed by multiple outlets — Coverage and transcripts highlight strong revenue growth and an EPS beat for Q4, supporting the narrative of improving operations and profitability. NAGE Tops Q4 Earnings (Zacks)
• Neutral Sentiment: Price target tweak but rating intact — Canaccord trimmed its price target from $14 to $13 while maintaining a “buy” rating, signaling continued analyst conviction but a more conservative valuation. Canaccord Price Target Update (Benzinga)
• Neutral Sentiment: HC Wainwright updated multi-quarter and FY2027 EPS models — the firm published a full set of quarterly and FY2027 estimates (FY2027 ~$0.37 EPS), providing a new baseline for investor expectations (mixed across quarters).
• Negative Sentiment: Revenue guidance below street estimates — Niagen issued FY2026 revenue guidance of $142.4M–$148.8M versus a consensus around $153.3M, which reduces near-term top-line visibility and likely pressured the share price despite the quarterly beat. Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: Analyst cuts to FY2026 and near-term quarters — HC Wainwright reduced FY2026 EPS (from $0.38 to $0.33) and cut Q2 2026 materially, which may weigh on sentiment as models are reset lower despite stronger Q4 results.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.